Latest News
TR-1 – Notification of Major Holdings
16 April 2019
Tiziana, a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today releases the TR-1 forms appended to this announcement.
Tiziana announces financial results for year ending 31 December 2018
04 April 2019
Tiziana today announces its financial results for the year ended 31 December 2018.
Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
20 March 2019
Tiziana announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA)
Directorate Change
07 February 2019
Tiziana today announces that Riccardo Dalla-Favera MD has resigned from his role as Non-Executive Director of the Company. The Company is grateful to Dr Favera for his time, expertise and commitment to the Company.
Exercise of Warrants & Issue of Equity
11 December 2018
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Exercise of Warrants & Issue of Equity
New York/London, 11 December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA...
Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
03 December 2018
New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase...